Case Report

Intravenous Immunoglobulin for Overwhelming Postsplenectomy Infection

Kensuke Nakamura, Yuji Takahashi, Tomohiro Sonoo, Hideki Hashimoto
Department of Emergency and Critical Care Medicine, Hitachi General Hospital, Hitachi, Ibaraki, Japan

Abstract

Overwhelming postsplenectomy infection (OPSI) is a life-threatening condition causing fulminant bacteremia in asplenic patients. Intravenous immunoglobulin (IVIG) therapy is theoretically effective for OPSI. Herein, we present a case of OPSI treated successfully with IVIG, along with results of a literature review. An asplenic 70-year-old male with acute ischemic stroke presented with rapid and fulminant septic shock from pneumococcus pneumonia and bacteremia. Resuscitation and antibiotics including IVIG therapy were instituted. The patient survived with favorable outcomes. We analyzed all case reports or case series of OPSI from 1971 through 2017. Cases with IVIG treatment showed a significantly higher survival rate than those without IVIG, even with multivariable regression analysis, suggesting IVIG as an independent predictive factor for survival. It suggests that IVIG is effective for OPSI and that it can be regarded as an adjunctive treatment option for OPSI.

Keywords: Intravenous immunoglobulin, overwhelming postsplenectomy infection, sepsis, splenectomy

Introduction

Overwhelming postsplenectomy infection (OPSI), a life-threatening condition, causes fulminant bacteremia in asplenic patients. The spleen is a crucially important organ to kill intravascular bacteria. Most notably, spleen marginal zone B cells produce specific antibodies for the encapsulated bacteria, which strongly resist host defenses and opsonization with specific antibodies necessary for phagocytosis.[1,2] Therefore, OPSI has a mortality rate of 50%–70%, once it develops.[3,4]

Streptococcus pneumoniae is the most frequent and problematic bacteria in OPSI because it is fulminant, its capsular polysaccharides especially resist macrophages, and specific antibodies are crucial for phagocytosis. As vaccine prevention for OPSI is recommended to increase specific antibodies, intravenous immunoglobulin (IVIG) therapy is theoretically effective for OPSI with antibody supplementation.[5] Moreover, IVIG has other theoretically beneficial effects for pneumococcal sepsis, such as inhibition of complement activity, neutralization of harmful toxins,[6,7] and anti-inflammatory immunomodulation,[8-10] some of which can be achieved without specific antibodies.

However, no report of the relevant literature describes a clinical study of specific treatments, including IVIG, for OPSI. Reasons might be that OPSI is a rare condition and that it is often fulminant. For that reason, it is difficult to collect cases and conduct prospective studies.

Herein, we present a case of OPSI that was treated successfully with ceftriaxone and supportive medical care including IVIG. We reviewed the literature of case reports of OPSI published in English and Japanese, including this case, and analyzed the efficacy of IVIG for OPSI treatment.

Case Report

A 70-year-old male with sudden headache and deteriorating consciousness was transported by ambulance to our emergency room. He had undergone resection of a pancreatic
tumor and prostatic cancer 2 years prior. Examination revealed body temperature of 36.0°C, heart rate of 79/min irregular, blood pressure of 123/70 mmHg, oxygen saturation of 100% (O2 10 l/min), respiratory rate of 12/min, Japan Coma Scale of III-100, and Glasgow Coma Scale of E1V2M5. His pupils were 2 mm/4 mm. Light reflex was ±/+. Left concomitant deviation was observed. He presented with right paresis. Laboratory findings showed a white blood cell count (WBC) of 7800/μl and C-reactive protein (CRP) of 0.23 mg/dl. Results of other examinations were within normal limits. An electrocardiogram showed an atrial fibrillation rhythm. Multiple brain infarctions were observed in diffusion-weighted images obtained from magnetic resonance imaging. No thrombus was detected by transthoracic echocardiography, however, left atrial thrombus was identified by transesophageal echocardiography after intensive care with mechanical ventilation. Carotid echography was not performed. Cardiogenic cerebral infarction was diagnosed. He was admitted to the emergency ward.

After admission, conscious disturbance worsened. He was intubated. Unfractionated heparin 15,000 U and edaravone 30 mg × 2 were administered. In the middle of the night on the 2nd day from admission, he suddenly developed a fever of 38.5°C, followed by a rapid drop of blood pressure 4 h after the fever. We immediately treated and evaluated him as septic shock. Laboratory findings at that point were WBC 28,300/μL, hemoglobin 14.3 g/dL, platelet count 25.6 × 10⁴/μL, total protein 6.2 g/dL, albumin 3.4 g/dL, total bilirubin 0.7 mg/dL, aspartate aminotransferase 22 U/L, alanine aminotransferase 16 U/L, lactase dehydrogenase 194 U/L, alkaline phosphatase 189 U/L, creatine kinase 114 U/L, blood urea nitrogen 11.0 mg/dL, creatinine 0.99 mg/dL, C-reactive protein 1.38 mg/dL, thrombin time 79.0%, activated partial thromboplastin time 66.0 s, and fibrinogen 686 mg/dL.

*S. pneumoniae* were detected in blood and sputum cultures. X-ray and whole-body computed tomography, for further evaluation of septic origin, revealed slight infiltration in the lower right lung field that was not apparent on admission [Figure 1a] and revealed that he had no spleen [Figure 1b]. It appears to have been resected during the pancreatic tumor operation. A spinal fluid test was normal. The patient was diagnosed as having community-acquired pneumonia by *Pneumococcus* and OPSI.

He was transferred to the intensive care unit. Administration of ceftriaxone 2 g × 2 and IVIG 5 g × 3 days (This dose regimen was covered by the national health insurance. His body weight was 60 kg) was started immediately, with fluid resuscitation, 0.5 γ noradrenaline and mechanical ventilation. Edaravone might be beneficial for septic condition. However, we discontinued its administration because severe infection is a contraindication in Japan. The patient’s condition improved slowly. Catecholamines were reduced. The patient was extubated and free from mechanical ventilation on day 4, but the catecholamine-dependent condition was prolonged. Noradrenaline was discontinued on the 8th day. Unfractionated heparin 15,000 U/day was continued until day 8 and switched to warfarin. He was moved to a different hospital for rehabilitation of brain infarction on the 9th day from admission.

**DISCUSSION AND CONCLUSIONS**

This case was very rapid and fulminant OPSI, in which septic shock was developed 4 h after fever. Although intensive care including mechanical ventilation was needed, he survived with favorable outcomes. It would be important to aware OPSI early and to start the treatments for sepsis.

In addition, we present a review of international and Japanese case reports of OPSI. We searched for the terms OPSI, splenectomy, and post-splenectomy sepsis from 1971 through 2017 in MEDLINE, PubMed, and Japan Medical Abstracts Society up to July 10, 2017. All OPSI case reports or case series that had been reported in English or Japanese were included. Studies on parasite infection were excluded. Treatment induction from onset was determined as the time to appropriate antibiotic therapy from the first presentation. Survival analysis was applied using the Wilcoxon test with dead/alive outcome and the observation period as factors. Nominal logistic regression analysis was applied to elucidate mortality. Univariate logistic regression analysis was conducted at first in each factor. Then, multivariable logistic regression analysis was performed with the factors strongly related to mortality in univariate analysis. All statistical analyses were conducted using software (JMP 10; SAS Institute Inc. Tokyo, Japan). *P* < 0.05 was considered statistically significant.

Sixty-nine OPSI case series were extracted including our case: 23 English-language case reports and 46 Japanese-language case reports [Table 1]. The most frequent pathogen was *S. pneumoniae* and its mortality was high. Twenty patients were treated with IVIG. There was no description of IVIG for the other 49 patients. We designated the former as the IVIG-treated group and the latter as the non-IVIG group. Survival curves with/without IVIG are depicted in Figure 2. Seven-day-survival was 85.0% with IVIG and 59.5% without IVIG: the survival rate was statistically significantly higher with IVIG treatment (*P* = 0.0046) [Figure 2a]. Thirty-day-survival was
Table 1: The review of case reports of overwhelming postsplenectomy infection

| Case | Reported year | Age | Sex | Reason for splenectomy | Onset from splenectomy | Treatment from onset | Pathogen | Culture | Antibiotics | DIC | Steroid therapy | IVIG | Outcome | Reference |
|------|---------------|-----|-----|-------------------------|------------------------|----------------------|----------|---------|-------------|-----|----------------|------|----------|-----------|
| 1    | 1979          | 41  | Male| Gastric Ca ope          | 6 years                | 1 day                | S. pneumoniae     | Blood   | ABPC, GM      | +   | PSL 40 mg     | -    | D        | 25        |
| 2    | 1979          | 59  | Male| Trauma                  | 35 years               | 2 day                | S. pneumoniae     | Spinal fluid | PCG          | +   | -             | -    | D        | 26        |
| 3    | 1982          | 44  | Male| Spleen rupture          | 20 years               | 12 h                 | S. pneumoniae     | Spinal fluid | Blood        | +   | -             | -    | S        | 27        |
| 4    | 1983          | 37  | Female| Trauma                 | 25 years               | 16 h                 | S. pneumoniae     | Blood   | PCG, CTM, GM | -   | -             | -    | D        | 28        |
| 5    | 1984          | 13  | Male| Osteopetrosis           | 9 years                |                      | S. pneumoniae     | Blood   | PCG          | -   | -             | -    | D        | 29        |
| 6    | 1985          | 27  | Male| Splenic hyperplasia     | 6 years                | 8 h                  | Group B Streptococcus | Blood | PCG          | +   | -             | +    | S        | 30        |
| 7    | 1986          | 54  | Male| Spleen thrombosis       | 26 years               | 1 day                | S. pneumoniae     | Spinal fluid | LMOX, FOM, AMK | -   | -             | -    | S        | 31        |
| 8    | 1987          | 26  | Female| ITP                    | 17 years               | 7 day                | S. pneumoniae     | Spinal fluid | LMOX, ABPC, PCG | -   | -             | -    | S        | 32        |
| 9    | 1987          | 70  | Male| Gastric Ca ope          | 5 days                 | 1 day                | Pepto-streptococcus | Pleural effusion | LMOX, GM     | +   | -             | +    | D        | 33        |
| 10   | 1988          | 39  | Male| Anemia                  | 1 month                | 5 h                  | Pepto-streptococcus | Blood  | PCG          | +   | -             | -    | D        | 34        |
| 11   | 1989          | 26  | Female| Lymphoma              | 20 years               | 3 days               | CTX, CMNX, IPM    | Blood  | ABPC, MNZ, GM | +   | -             | -    | D        | 35        |
| 12   | 1990          | 35  | Female| Anemia                | 20 years               | 3 days               | CTX, CMNX, IPM    | Blood  | ABPC, MNZ, GM | +   | -             | -    | D        | 36        |
| 13   | 1992          | 36  | Male| Lymphoma, splenic rupture | 18 years               |                      | S. pneumoniae     | Blood  | CTX, FMOX, CMNX, IPM | +   | mPSL 500 mg | -    | D        | 37        |
| 14   | 1992          | 56  | Male| Macroglobulinemia       | 2 years                |                      | S. pneumoniae     | Blood  | PIPC        | -   | -             | -    | D        | 37        |
| 15   | 1992          | 13  | Male| ITP                     | 8 years                | 12 h                 | S. pneumoniae     | Blood  | +           | -   | -             | -    | S        | 38        |
| 16   | 1992          | 36  | Male| Hereditary spherocytosis | 31 years               | 12 h                 | S. pneumoniae     | Blood  | +           | +   | -             | -    | D        | 39        |
| 17   | 1993          | 27  | Female| Trauma               | 3 years                | 16 h                 | S. pneumoniae     | Spinal fluid | Blood        | +   | -             | -    | D        | 40        |
| 18   | 1993          | 79  | Female| splenic cyst          | 2 years                | 19 h                 | S. pneumoniae     | Blood  | ABPC, TOB    | -   | -             | -    | S        | 41        |
| 19   | 1993          | 16  | Male| ITP                     | 7 years                |                      | S. pneumoniae     | ABPC, TOB | +           | +   | -             | -    | S        | 41        |
| 20   | 1994          | 34  | Male| Trauma                  | 5 years                | 10 h                 | S. pneumoniae     | Blood  | +           | +   | -             | -    | D        | 42        |
| 21   | 1997          | 26  | Female| Trauma                | 10 years               | 1 days               | S. pneumoniae     | Blood  | +           | +   | -             | -    | D        | 43        |
| 22   | 1997          | 63  | Female| Pancreatic Ca ope       | 4 years                | 23 days              | E. faecalis, MRSA | Blood  | PCG, CTX    | +   | -             | -    | S        | 44        |
| 23   | 1998          | 39  | Female| ITP                   | 8 years                | 4 days               | S. pneumoniae     | CTX, ABPC | -           | Dexamethasone | +    | 8 g          | S        | 45        |
| 24   | 1998          | 37  | Male| Trauma                  | 11 years               | 16 h                 | C. canimorsus     | Blood  | PCG, mezlocillin, GM, CPFX | +   | -             | -    | S        | 46        |
| 25   | 1999          | 77  | Male| Hereditary spherocytosis | 13 years               | 3 days               | S. pneumoniae     | Spinal fluid | IPM/CS, ABPC, CTX | -   | -             | +    | S        | 47        |

Contd...
| Case | Reported year | Age | Sex | Reason for splenectomy | Onset from splenectomy | Treatment from onset | Pathogen | Culture | Antibiotics | DIC | Steroid therapy | IVIG | Outcome | Reference |
|------|---------------|-----|-----|-------------------------|------------------------|----------------------|----------|---------|-------------|-----|----------------|------|---------|-----------|
| 26   | 2000          | 22  | Female | Hereditary spherocytosis | 11 years | 7 days | *S. pneumoniae* | Blood | CTX | + | - | - | S | 48 |
| 27   | 2002          | 23  | Female | ITP | 2 years | 2 days | *S. pneumoniae* | Blood | - | - | - | D | 49 |
| 28   | 2002          | 30  | Male | Gastric Ca ope | 1 year | 1 days | *S. pneumoniae* | Blood | MEPM | + | - | - | D | 50 |
| 29   | 2003          | 39  | Male | Trauma | 30 years | 1 days | *S. pneumoniae* | Spinal fluid | PAPM/BP | + | mPSL 1000 mg | + | S | 51 |
| 30   | 2004          | 52  | Male | | | | | | | | | | |
| 31   | 2005          | 62  | Female | Cirrhosis | 10 years | 1 day | *S. pneumoniae* | Blood | ABPC, CTX | + | - | + | D | 52 |
| 32   | 2005          | 29  | Male | ITP | 5 years | 1 day | *S. pneumoniae* | Blood | PIPC, GM, MEPM | - | - | + | S | 53 |
| 33   | 2005          | 51  | Male | Pancreatic cyst | 9 years | 1 day | *S. pneumoniae* | Sputum | + | - | - | D | 54 |
| 34   | 2005          | 75  | Male | Gastric Ca ope | 9 years | 3 days | *S. pneumoniae* | Sputum | + | - | - | D | 55 |
| 35   | 2005          | 69  | Male | Spleen hypoplasia | 9 years | 2 days | *S. pneumoniae* | Blood | + | - | - | D | 55 |
| 36   | 2005          | 64  | Male | Hereditary spherocytosis | 3 years | 2 days | *S. pneumoniae* | Sputum | + | - | - | S | 55 |
| 37   | 2006          | 30  | Female | Trauma | 22 years | 3 days | *S. pneumoniae* | Blood | + | mPSL 1000 mg | + | S | 56 |
| 38   | 2007          | 46  | Male | Trauma | 28 years | 2 days | *S. pneumoniae* | Blood sputum | + | Hydrocortisone 200 mg | + | S | 57 |
| 39   | 2007          | 20  | Male | Trauma | 5 years | 2 days | *S. pneumoniae* | Blood sputum | + | Dexamethasone 12 mg | + | D | 58 |
| 40   | 2007          | 52  | Male | ITP | 11 years | 12 h | *C. canimorsus* | Blood | + | - | - | S | 59 |
| 41   | 2008          | 50  | Female | ABO-incompatible renal transplantation | 11 years | 3 days | *S. pneumoniae* | Blood sputum | + | mPSL 20 mg | + | S | 60 |
| 42   | 2008          | 21  | Male | ITP | 8 years | 15 days | *S. pneumoniae* | Blood | + | - | - | D | 61 |
| 43   | 2008          | 43  | Female | ITP | 15 years | 2 days | *S. pneumoniae* | Blood | MEPM | + | - | - | D | 61 |
| 44   | 2008          | 47  | Female | Trauma | 8 years | 1 day | *S. pneumoniae* | Spinal fluid | CTX | - | - | - | S | 61 |
| 45   | 2009          | 61  | Male | Trauma, spleen hypoplasia | 20 years | 1 day | *S. pneumoniae* | Blood | + | - | - | D | 62 |
| 46   | 2009          | 25  | Male | ITP | 22 years | 1 day | *S. pneumoniae* | Blood | PCG, MEPM, CTX | + | + | - | S | 63 |
| 47   | 2009          | 72  | Male | AIHA | 8 months | 1 day | *C. albicans* | Blood | CPFX, FLCZ | - | mPSL 1000 mg | - | S | 64 |
| 48   | 2009          | 47  | Male | ABO-incompatible liver transplantation | 4 months | 1 day | *S. pneumoniae* | Blood | CPFX, ST, MCFG | - | - | + | S | 65 |
| 49   | 2010          | 59  | Female | Hepatitis C | 3 years | 3 days | *S. pneumoniae* | Blood | CTX, VCM | - | - | - | S | 66 |
| 50   | 2010          | 34  | Female | ITP | 14 years | 2 days | *S. agalactiae* | Blood | MEPM, ABPC | + | - | + | S | 67 |
Table 1: Continued...

| Case | Reported year | Age | Sex | Reason for splenectomy | Onset from splenectomy | Treatment from onset | Pathogen | Care | Antibiotics | DIC | Steroid therapy | IVIG | Outcome | Reference |
|------|----------------|-----|-----|------------------------|------------------------|---------------------|----------|-----|-------------|-----|-----------------|------|----------|-----------|
| 51   | 2010           | 64  | Female | Total gastric resection | 1 year | Blood spinal fluid, CTX | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 68        |
| 52   | 2011           | 68  | Male | Total gastric resection | 20 days | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 69        |
| 53   | 2011           | 68  | Male | Gastric Carpe | 12 h | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 70        |
| 54   | 2011           | 41  | Female | Total gastric resection | 21 weeks | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 71        |
| 55   | 2012           | 64  | Female | Total gastric resection | 2 weeks | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 72        |
| 56   | 2012           | 68  | Male | Total gastric resection | 20 days | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 73        |
| 57   | 2012           | 45  | Male | Trauma | 1 day | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 74        |
| 58   | 2012           | 66  | Female | Total gastric resection | 3 years | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 75        |
| 59   | 2012           | 41  | Male | Total gastric resection | 9 months | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 76        |
| 60   | 2013           | 32  | Female | Total gastric resection | 6 months | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 77        |
| 61   | 2013           | 52  | Female | Total gastric resection | 9 months | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 78        |
| 62   | 2013           | 63  | Male | Total gastric resection | 5 years | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 79        |
| 63   | 2014           | 58  | Female | Total gastric resection | 1 day | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 80        |
| 64   | 2015           | 38  | Female | Total gastric resection | 10 years | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 81        |
| 65   | 2015           | 39  | Male | Trauma | 1 day | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 82        |
| 66   | 2016           | 70  | Male | Splenectomy | 2 years | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 83        |
| 67   | 2016           | 55  | Female | Splenic artery rupture | 10 years | Blood | S. pneumoniae | Blood | CTRX, PPA | - | Decamethasone | - | S | 84        |

DIC+: There was obvious coagulopathy according to the criteria of International Society on Thrombosis and Hemostasis or that of Japanese Association for Acute Medicine. DIC-: There was no coagulopathy or not described about coagulation. S. pneumoniae: Streptococcus pneumonia, E. faecalis: Enterococcus faecalis, C. albicans: Candida albicans, H. influenza: Haemophilus influenza, E. coli: Escherichia coli, IVIG: Intravenous immunoglobulin, DIC: Disseminated intravascular coagulopathy, ITP: Idiopathic thrombocytopenic purpura, PAP: Penicillin-resistant pneumococcal pneumonia.
Table 2: Logistic regression analyses for mortality

| Univariable logistic regression analysis | Multivariable logistic regression analysis |
|----------------------------------------|------------------------------------------|
| Published year of the Christian era     | 0.98 (0.93-1.04)                         | 0.75 (0.37-1.03) |
| Treatment from onset                    | 0.68 (0.07-6.19)                         | 0.023*           |
| DIC                                    | 0.00005(6.81e-12-1.25)                   | 0.059            |
| Steroid therapy                        | 2.83 (0.93-9.86)                        | 0.067            |
| IVIG                                   | 0.76 (0.26-2.15)                        | 0.61             |
| IVIG                                   | 0.20 (0.042-0.69)                       | 0.0099*          |

OR: Odds ratio, CI: Confidence interval, IVIG: Intravenous immunoglobulin, DIC: Disseminated intravascular coagulopathy p<0.05 was considered statistically significant with *

Figure 2: Survival analysis with/without intravenous immunoglobulin. Black line, with intravenous immunoglobulin treatment; Gray line, without intravenous immunoglobulin: a: survival analysis for 7 days; b: survival analysis for 30 days

We conducted univariate logistic regression analyses for mortality [Table 2]. It is particularly interesting that disseminated intravascular coagulopathy (DIC) was found to be a strong risk factor for mortality. The mortality odds ratio of DIC was 17.3 (P = 0.0009) in multiple logistic regression analysis, partly because DIC represents the severity of the infectious condition. Treatment induction from onset was also correlated with survival (odds ratio 0.75, P = 0.089), contrary to expectations. Because they might not be fulminant, they survived without early treatment induction. In addition, IVIG treatment was a statistically significant and independent factor for survival (odds ratio 0.19, P = 0.023).

The clinical course of OPSI is often fulminant. Although antibiotics and supportive medical care are the cornerstone of therapy, adjunctive IVIG is theoretically effective for OPSI. The most important effect of IVIG in the treatment of OPSI is the supplementation of specific antibodies. As some experimental studies have demonstrated the efficacy of IVIG in OPSI,[14,15] we demonstrated in a previous study that IVIG was effective in OPSI mouse model, which was due to specific antibodies.[16] The efficacy of IVIG for survival was dose dependent on the amounts of specific antibodies to causative bacteria. There are many serotypes in capsular polysaccharides of pneumococcus.[16] Polyclonal IVIG includes specific antibodies for various serotypes of pneumococcus, mainly in IgG2 fractionate.[17]

For OPSI, IVIG effects other than the specific antibodies supplement might be also effective. Nonspecific neutralization of some toxins might prolong survival. Streptococcal sepsis releases superantigen exotoxins;[18,19] IVIG reportedly neutralizes them.[20] Moreover, IVIG has various immunomodulatory and anti-inflammatory effects.[10,21] In addition, IVIG suppresses the activation of leukocytes including macrophages and B cells.[22,23] This suppression is reportedly beneficial for sepsis treatment by preventing late-onset anergy.[24]

The analysis of this article has several limitations. The first is the possibility of publication bias. Second, we assigned the reports that included no description about IVIG to the non-IVIG group. Third, this review included old and new reports together, from 1971 through 2017, among which the treatment of sepsis probably differed.

In conclusion, we presented a case of OPSI which was treated successfully with IVIG. IVIG might be effective as an adjunctive treatment option for OPSI, as demonstrated by a review of the literature.

Consent to publish
We obtained written consent to report and publish the case from the patient.

Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given his consent for his images and other clinical information to be reported in the journal. The patient understands that his name and initial will not be published, and due efforts will be made to conceal identity, but anonymity cannot be guaranteed.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

REFERENCES
1. Zandvoort A, Timens W. The dual function of the splenic marginal zone: Essential for initiation of anti-T1-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002;130:4-11.
2. Haas KM, Poe JC, Steeber DA, Tedder TF. B-1a and B-1b cells exhibit distinct developmental requirements and have unique functional roles in innate and adaptive immunity to S. pneumoniae. Immunity 2005;23:7-18.
Nakamura, et al.: IVIG for overwhelming postsplenectomy infection

3. Styrt B. Infection associated with asplenia: Risks, mechanisms, and prevention. Am J Med 1990;88:33N-42N.
4. Holdsworth RJ, Irving AD, Cuschieri A. Postsplenectomy sepsis and its mortality rate: Actual versus perceived risks. Br J Surg 1991;78:1031-8.
5. Nakamura K, Doi K, Okamoto K, Arai S, Ueha S, Matushima K, et al. Specific antibody in IV immunoglobulin for postsplenectomy sepsis. Crit Care Med 2013;41:e163-70.
6. Davville T, Milligan LB, Laffoon KK. Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun 1997;65:366-72.
7. Yanagisawa C, Hanaki H, Natae T, Sunakawa K. Neutralization of exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 2007;13:368-72.
8. Aukrust P, Müller F, Svenson M, Nordøy I, Bendtzen K, Fløland SS. Administration of intravenous immunoglobulin (IVIG) in vivo-down-regulatory effects on the IL-1 system. Clin Exp Immunol 1999;115:136-43.
9. Bailey JK, McCall J, Smith S, Kagan RJ. Correlation of internal jugular vein/common carotid artery ratio to central venous pressure: A pilot study in pediatric burn patients. J Burn Care Res 2012;33:89-92.
10. Shankar-Hari M, Spencer J, Sewell WA, Rowan KM, Singer M. Bench-to-bedside review: Immunoglobulin therapy for sepsis-biological plausibility from a critical care perspective. Crit Care 2012;16:206.
11. Kato S, Hussein MH, Kakita H, Goto T, Daoud GA, Kato T, et al. Edaravone, a novel free radical scavenger, reduces high-mobility group box 1 and prolongs survival in a neonatal sepsis model. Shock 2009;32:586-92.
12. Li Z, Ma QQ, Yan Y, Xu FD, Zhang XY, Zhou WQ, et al. Edaravone attenuates hippocampal damage in an infant mouse model of pneumococcal meningitis by reducing HMGB1 and iNOS expression via the Nrf2/HO-1 pathway. Acta Pharmacol Sin 2016;37:1298-306.
13. Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 2007;11:292-6.
14. Offenhartl K, Christensen P, Gullstrand P, Prellner K, Seger RA. Treatment of pneumococcal postsplenectomy sepsis in the rat with human gamma-globulin. J Surg Res 1986;40:198-201.
15. Camel JE, Kim KS, Tchejeyan GH, Mahour GH. Efficacy of passive immunotherapy in experimental postsplenectomy sepsis due to Haemophilus influenzae type b. J Pediatr Surg 1993;28:1441-4.
16. Mufson MA, Hao JB, Stanek RJ, Norton NB. Clinical features of patients with recurrent invasive Streptococcus pneumoniae disease. Am J Med Sci 2012;343:303-9.
17. Mikolajczyk MG, Concepcion NF, Wang T, Frazier D, Golding B, Frasch CE, et al. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin Diagn Lab Immunol 2004;11:1158-64.
18. Kohl M. Bacterial pyrogenic exotoxins as superantigens. Clin Microbiol Rev 1995;8:411-26.
19. The Editors. Host-microbe interactions in the pathogenesis of invasive group A streptococcal infections. J Med Microbiol 2000;49:849-52.
20. Darenberg J, Ihendyane N, Spijlin J, Aufwerber E, Haidl S, Follin P, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: A European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003;37:333-40.
21. Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, Neel BG, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007;26:67-78.
22. Rhoades CJ, Williams MA, Kelsey SM, Newland AC. Monocyte-macrophage system as targets for immunomodulation by intravenous immunoglobulin. Blood Rev 2000;14:14-30.
23. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
24. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Sibbiri S, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IV Ig in primary immunodeficiencies. J Autoimmun 2011;36:9-15.
25. Hanawa M, Kobayashi H, Oishi M, Fujisawa H, Matsuoka M. A case of Waterhouse-Friderichsen syndrome after splenectomy (author’s transl). Rinsho Ketsueki 1979;20:308-13.
26. Tsusaka T, Takao S, Genju O. Report of a case with the syndrome of asplenia, pneumococcal sepsis, and disseminated intravascular coagulation. Int Med 1979;43:4.
27. Tan KH. Fulminating pneumococcal septicaemia and meningitis in an adult twenty years after splenectomy for a ruptured spleen. Neth J Surg 1982;34:222-4.
28. Sasaki W, Bergholz M, Kehl A, Seifert J, Hamelmann H. Overwhelming infection after splenectomy in spite of some spleen remaining and splenosis. A case report. Klin Wochenschr 1983;61:1075-9.
29. Tesluk GC, Thomas CG Jr, Benjamin JT, McMillan CW. Fatal overwhelming postsplenectomy sepsis following autologous splenic transplantation in severe congenital osteopetrosis. J Pediatr Surg 1984;19:269-72.
30. Fish HR, Chia JK, Shikir KM. Postsplenectomy sepsis caused by group B streptococcus (S. agalactiae) in an adult patient with diabetes mellitus. Diabetes Care 1985;8:689-9.
31. Joji K, Keigo Y, Tatsuo I, Tatsuyuki I, Kiyoshi M. A survival case of overwhelming postsplenectomy infection (OPSI) syndrome-pneumococcal meningitis developing 26 years after splenectomy. J Japanese Soc Intr Med 1986;75:4.
32. Yousuke S, Yoshihiro S, Yoshiaki H, Masaro K. A case of pneumococcal meningitis which occurred seventeen years after splenectomy. Neurol Med 1987;27:3.
33. Masatomo Y, Tsukasa H, Masanori T, Hideyoshi H, Katsunori T, Nobuyoshi K. Postsplenectomy sepsis. Emerg Med 1987;11:5.
34. Shigeto K, Takeshi T, Mitsuhiro T, Naoki S, Masakuni S, Yoshihisa W, et al. A case with combined immunodeficiency died with overwhelming post-splenectomy infection syndrome after splenosis. J Japanese Clin Immunol 1989;12:5.
35. Waldron DJ, Harding B, Duigan J. Overwhelming infection occurring in the immediate post-splenectomy period. Br J Clin Pract 1989;43:421-2.
36. Aiboshi J, Hiroshi H, Yamamoto Y, Kunihito M, Kazuhiro Y, Kazunari M, et al. A case of postsplenectomy. KANTO J Japanese Assoc Acute Med 1990;11:5.
37. Tatsaka T, Nagai M, Ikeda K, Sasaki K, Murata M, Taoka T, et al. Post-splenectomy meningitis in patients with lymphoid malignancy. Intern Med 1992;31:1137-8.
38. Yiniz LW, Kobichi A, Toshiyuki Y, Kei S, Shigeru O. Postsplenectomy pneumococcal sepsis developed 2 year after pneumococcal vaccination. J Infect Chemother 1992;66:2.
39. Bridgen ML. Overwhelming postsplenectomy infection still a problem. West J Med 1992;157:440-3.
40. Kei K, Kazuyoshi S, masazumi A, Akhiro I, Yasumasa H, Yoshihito N. A case of overwhelming postsplenectomy infection of pneumococcal sepsis three year after splenectomy. Med J Tosei General Hospital 1999;2:6.
41. Osamu I, Hiroshi T, Kazuhiro H, Asakazu T, Zyun T, Zyunikichi S. Two cases of overwhelming postsplenectomy infection. Okinawa Med J 1993:31:2.
42. Mitsuko M, Yukihiro K, Tokyo M, Tsuyoshi A, Hiro U. Overwhelming postsplenectomy infection accompanied by Waterhouse-Friderichsen syndrome. J Japanese Assoc Acute Med 1994;5:4.
43. Urata Y, Hasegawa M, Hasegawa H, Shikano M, Kawasaki S, Imoto M. A fatal case of overwhelming postsplenectomy infection syndrome developing 10 years after splenectomy. Nihon Rinsho Ketsueki 1979;20:308-13.
44. Murao S, Hosokawa H, Hosokawa Y, Isha T, Takahara J. Discitis, infectious arthritis, and bacterial meningitis in a patient with pancreatic diabetes. Intern Med 1997;36:443-5.
45. Ken Y, Shigeo I, Hitoo T, Makoto U. A survival case of fulminating pneumococcal meningitis as overwhelming postsplenectomy infection (OPSI) syndrome. Clin Neur 1998;38:5.
46. Sawmilljer CJ, Dudrick SJ, Hamzi M. Postsplenectomy Capnocytophaga canimorsus sepsis presenting as an acute abdomen. Arch Surg 1998;133:1362-5.
Overwhelming post-splenectomy infection (OPSI) syndrome still candidate for medical ICU. Braz J Infect Dis 2007;11:4.

Tatsuhito M, Yasui T, Toru K, Toshinori S, Tsuyoshi Y, Yasushi H, et al. Overwhelming postsplenectomy infection in a patient with hyposplenism and postsplenectomy: Importance of health precaution. J Japan Soc Emerg Med 2005;8:6.

Masanori I, Junichiro S, Yuji H, Hiroshi Y, Takayuki T, et al. A survival case of ABO-incompatible liver transplantation complicated with diabetes mellitus. Kitakanto Med J 2009;59:6.

Naoki K, Jyunrou I, Taizou T, Hiroshi I, Yasuei O, Seiichirou S. Overwhelming postsplenectomy infection (OPSI) syndrome. Brain Nerve 2003;55:4.

Tadashi K, Junichiro H, Tomotsugu Y, Shogo T, Kenichi S, Kennichiro F, Syunsuke N, Takeshi Y, Yasusi M, Toru A. A case of overwhelming postsplenectomy infection syndrome: A case report. Forensic Sci Int 2004;146 Suppl: S55-6.

Naoki K, Jyunrou I, Taizou T, Hiroshi I, Yasuei O, Seiichirou S. Overwhelming postsplenectomy infection syndrome with meningitis and multiple organ failure as overwhelming postsplenectomy infection (OPSI) syndrome. Brain Nerve 2003;55:4.

Overwhelming postsplenectomy infection (OPSI) developing repeatedly after total gastrectomy-report of a successfully treated case. J Japan Surg Assoc 2012;73:5.

Yuzo N, Tomomi H, Takahiro I, Yasuhiko T, Jun M, Naoko A. A case of overwhelming postsplenectomy infection 34 years after splenectomy. Okinawa Med J 2012;50:3.

Atsuko H, Noriyuki S, Kenichi K, Takuya N, Masashi A, Shinya T. Acute of overwhelming postsplenectomy infection due to Mycoplasma pneumoniae in an asplenic cirrhotic patient: Case report. BMC Infect Dis 2011;11:162.

Noriyuki M, Ryuichi S, Eriko T, Nana S, Maki M, Toshitaka M, et al. Acase of overwhelming postsplenectomy infection with purpura fulminans due to pneumococcal infection. J Japan Soc Med 2012;101:4.

Chie K, Yasuyuki K, Atsushi N, Shigeto M, Mikako K, Keiichi N. Overwhelming postsplenectomy infection (OPSI) in a patient who had undergone gastrectomy-report of a case. J Japan Surg Assoc 2012;73:5.

Yusuke N, Tomomi H, Takahiro I, Yasuhiko T, Jun M, Naoko A. A case of overwhelming postsplenectomy infection syndrome with meningitis and multiple organ failure as overwhelming postsplenectomy infection (OPSI) syndrome: A case report and review of the literature. J Emerg Med 2012;43:758-63.

Koichi T, Yasutsugu S, Kohei N, Naoki T, Yugo N, Makoto I. Overwhelming postsplenectomy infection (OPSI) developing repeatedly after total gastrectomy-report of a successfully treated case. J Japan Surg Assoc 2013;74:5.

Takayuki S, Ken I, Yusuke M, Kazunobu I, Akiko H, Isao K. A fatal case of overwhelming postsplenectomy infection. J Japan Soc Intensive Care Med 2013;20:2.

Kenichiro Y, Yohei S, Kazuhiro K, Natsuo T, Satsuo T. Overwhelming postsplenectomy infection due to Mycoplasma pneumoniae in an asplenic cirrhotic patient: Case report. BMC Infect Dis 2011;11:162.

Morgan TL, Tomich EB. Overwhelming post-splenectomy infection (OPSI): A case report and review of the literature. J Emerg Med 2012;43:758-63.

Koichi T, Yasutsugu S, Kohei N, Naoki T, Yugo N, Makoto I. Overwhelming postsplenectomy infection (OPSI) developing repeatedly after total gastrectomy-report of a successfully treated case. J Japan Surg Assoc 2012;73:5.

Takakura S, Ken I, Yusuke M, Kazunobu I, Akiko H, Isao K. A fatal case of overwhelming postsplenectomy infection. J Japan Soc Intensive Care Med 2013;20:2.

Kenichiro Y, Yohei S, Kazuhiro K, Natsuo T, Satsuo T. Overwhelming postsplenectomy infection due to Mycoplasma pneumoniae in a patient with splenic hypoplasia. General Med 2014;15:4.

Kohei I, Yoshiaki I, Yuka S, Shigeru M, Ken O, Hiroshi T. A case of pneumococcal infection with paraplegia and purpura fulminans as complications. J Japan Assoc Acute Med 2015;26:6.

Sheng CF, Liu BY, Zhang HM, Zheng X. Overwhelming postsplenectomy infection. Genet Mol Res 2015;14:2702-6.

Takehiro N, Shunpei Y, Takahisa K, Motowo M, Hiroshi Y. Overwhelming postsplenectomy infection in a heavy drinker. Ann Kurashiki Central Hospital 2016;78:5.

Yutaru S, Kazuyoshi I, Yasuo K. Two cases of overwhelming postsplenectomy infection. Hinyokika Kiyo 2010;66:2-4.

Naoki H, Chikao Y, Taihei Y, Takeki A, Yukiko H, Tamotsu T, et al. Overwhelming post-splenectomy infection an asplenic ABO-incompatible renal transplant patient. J Japan Trans 2008;43:6.

Overwhelming post-splenectomy infection. Transplant Proc 2009;41:3941-4.